Accolades include Lawyer of the Year, Impact Deal of the Year, and Belgium Firm of the Year.
Eveline Van Keymeulen is a partner in Latham & Watkins' Brussels and Paris offices and Global Vice Chair of Latham & Watkins' Healthcare & Life Sciences Practice.
She advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food and beverage sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations, and general compliance matters.
In addition, Eveline has extensive experience advising on cannabis and hemp-based product regulations. She successfully challenged the legality of French hemp regulations in the first landmark case related to cannabidiol (CBD) products before the Court of Justice of the European Union (Case C-663/18, Kanavape). This transaction won the Creating New Standards award at the Financial Times European Innovative Lawyer Awards 2022.
Eveline has authored numerous articles and has been a featured speaker on EU regulatory matters at prominent conferences such as the Pharmaceutical Law Academy in Cambridge. She also serves on the editorial board of the European Pharmaceutical Law Review.
In addition, Eveline has been quoted in BBC Business Daily, Bloomberg, The Times, Les Echos, and other leading international business journals on life sciences regulatory and policy matters.
Ms. Van Keymeulen is recognized as one of the leading life sciences practitioners in France by Legal Media Group 2021, Best Lawyers 2021, and Euromoney’s Women in Business Law Expert Guide 2021
"Advisory Lawyer of the Year" and winner of "Impact Case of the Year" LMG Life Sciences 2021
"Ms. Van Keymeulen enters the rankings on the back of strong market recognition. She advises clients from the life sciences industries on regulatory mandates. Clients value her "high level of energy" with one source also appreciating her for being "extremely flexible and genuinely engaged" as well as having "a can-do attitude." Chambers, Pharma/Life sciences: Regulatory – France 2020
“Receives effusive praise from peers this year for her adeptness on matters such as marketing authorizations and product life cycle management.” Who’s Who Legal, Life Sciences 2020
“Brilliant and sharp. She can navigate hard legal issues but she can also make our industry and its challenges simple to understand when addressing a lay audience.” The Legal 500, Healthcare and Life Sciences – Belgium 2020